Evidence map›Paper›PMID 36409722›Full record

ArticlePloS one2022

Biomarkers of sickle cell nephropathy in Senegal.

El Hadji Malick Ndour, Khuthala Mnika, Fatou Guèye Tall, Moussa Seck, Indou Dème Ly, Victoria Nembaware, Gaston Kuzamunu Mazandu, Hélène Ange Thérèse Sagna Bassène, Rokhaya Dione, Aliou Abdoulaye Ndongo and 10 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07708714 (Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07708714 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2026 to 2032Enrolled250ConditionsSickle Cell Disease, Sickle Cell Anemia in ChildrenArmshydroxycarbamide
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. CKD in Migrants: From Epidemiology to Challenges.Kidney international reports · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 3 countries.

El Hadji Malick NdourDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.ORCID 0000-0002-0290-8675
Khuthala MnikaDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Fatou Guèye TallDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Moussa SeckNational Center of Blood Transfusion, Dakar, Senegal.
Indou Dème LyAlbert Royer National University Hospital of Children, Dakar, Senegal.
Victoria NembawareDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Gaston Kuzamunu MazanduDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Hélène Ange Thérèse Sagna BassèneAlbert Royer National University Hospital of Children, Dakar, Senegal.
Rokhaya DioneAlbert Royer National University Hospital of Children, Dakar, Senegal.
Aliou Abdoulaye NdongoDepartment of Pediatrics, Dantec National University Hospital, Dakar, Senegal.
Jean Pascal Demba DiopDepartment of Human Genetics, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Nènè Oumou Kesso BarryDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Moustapha DjitéDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Rokhaya Ndiaye DialloDepartment of Human Genetics, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Papa Madièye GuèyeDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Saliou DiopNational Center of Blood Transfusion, Dakar, Senegal.
Ibrahima DiagneDepartment of Pediatrics, Faculty of Health Sciences, Gaston Berger University, Saint-Louis, Senegal.
Aynina CisséDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Ambroise WonkamDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Philomène Lopez SallDepartment of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Dentistry, Cheikh Anta Diop University, Dakar, Senegal.
Centre Hospitalier National Universitaire de Fann · SNCheikh Anta Diop University · SNUniversity of Cape Town · ZAHôpital Aristide Le Dantec · SNJohns Hopkins University · USNational Health Laboratory Service · ZAUniversité Gaston Berger · SN

Funding

Sickle Africa Data Coordinating CenterU24HL135600 · NHLBI · UNIVERSITY OF CAPE TOWN · PI MULDER, NICOLA, WONKAM, AMBROISE · 2017 to 2025
$8.6M
NHLBI NIH HHS U24 HL135600
6 · The paper itself

Abstract

Sickle cell anemia (SCA) is caused by a single point variation in the β-globin gene (HBB): c.20A> T (p.Glu7Val), in homozygous state. SCA is characterized by sickling of red blood cells in small blood vessels which leads to a range of multiorgan complications, including kidney dysfunction. This case-control study aims at identifying sickle cell nephropathy biomarkers in a group of patients living with SCA from Senegal. A total of 163 patients living with SCA and 177 ethnic matched controls were investigated. Biological phenotyping included evaluation of glycemia, glucosuria, albuminuria, proteinuria, tubular proteinuria, serum creatinine, urine creatinine, urine specific gravity and glomerular filtration rate. Descriptive statistics of biomarkers were performed using the χ2 -test, with the significance level set at p<0.05. Patients living with SCA had a median age of 20 years (range 4 to 57) with a female sex frequency of 53.21%. The median age of the control participants was 29 years (range: 4-77) with a female sex frequency of 66.09%. The following proportions of abnormal biological indices were observed in SCA patients versus (vs.) controls, as follows: hyposthenuria: 35.3%vs.5.2% (p<0.001); glomerular hyperfiltration: 47.66%vs.19.75% (p<0.001), renal insufficiency: 5.47%vs.3.82% (p = 0.182); microalbuminuria: 42.38%vs.5.78% (p<0.001); proteinuria: 39.33%vs.4.62% (p<0.001); tubular proteinuria: 40.97%vs.4.73% (p<0.001) and microglucosuria: 22.5%vs.5.1% (p<0.001). This study shows a relatively high proportion of SCA nephropathy among patients living with SCA in Senegal. Microglucosuria, proteinuria, tubular proteinuria, microalbuminuria, hyposthenuria and glomerular hyperfiltration are the most prevalent biomarkers of nephropathy in this group of Senegalese patients with SCA.

Indexed as

Anemia, Sickle CellKidney DiseasesRenal InsufficiencyVascular DiseasesAdolescentAdultAgedAlbuminuriaBiomarkersCase-Control StudiesChildChild, PreschoolFemaleHumansMiddle AgedProteinuriaBiomarkers

Identifiers

PMID36409722
PMCPMC9678278
OpenAlexW4309495105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.